A panel of experts discuss potential drug-drug interactions that can occur between an FDA-approved treatment option for mild-to-moderate COVID-19 and concomitant medications.
Drug interactions can occur between an FDA-approved treatment option for adult patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease and concomitant medications a patient is taking. That’s why a panel of experts, featuring infectious disease physician-scientist Dr Daniel Griffin, virologist Dr Vincent Racaniello, cardiologist Dr Jayne Morgan, and clinical pharmacist Dr Samir Balile have come together to discuss approaches to managing potential drug-drug interactions appropriately.
| Contributor | Pfizer |
|---|---|
| Source | Pfizer |
| Date Content Reviewed | October 2024 |
| Future Review Date | December 2024 |
| Format | Video |
| Length | 32:37 |
